Androgen deprivation therapy may lead to cognitive impairment in prostate cancer patients

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is commonly called "chemo brain." Signs of cognitive impairment include forgetfulness, inability to concentrate, problems recalling information, trouble multi-tasking and becoming slower at processing information. The number of people who experience cognitive problems following cancer therapy is broad, with an estimate range of 15 to 70 percent.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Abstract Lipopolysaccharide-induced tumor necrosis factor alpha factor (LITAF), also called p53-induced gene 7 (PIG7), was identified as a transcription factor that activates transcription of proinflammatory cytokines in macrophages in response to lipopolysaccharide (LPS). Previous studies have identified LITAF as a potential tumor suppressor in several neoplasms, including prostate cancer, B-NHL, acute myeloid leukemia, and pancreatic cancer. However, the expression and function of LITAF in human glioma remain unexplained. The present study aimed to analyze the regulation of LITAF in gliomas. Data from The Cancer...
Source: Cellular and Molecular Neurobiology - Category: Cytology Authors: Tags: Cell Mol Neurobiol Source Type: research
We present a 66-year-old asymptomatic man who had incidental brain metastases detected on 68Ga-PSMA PET/CT, which was later confirmed on biopsy to be prostate adenocarcinoma. With newer androgen deprivation agents and improved imaging capabilities increasing the mean survival and thus the incidence of brain metastases from prostate cancer, it is important to consider this important differential not only in men who display neurological symptoms but also in men who are asymptomatic.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Bayer to present new data at ASCO 2019 highlighting commitment to evolve cancer treatment paradigmData from Bayer's growing oncology portfolio include new analyses on the company's precision oncology treatment larotrectinib, with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion: one on expanded data in pediatric patients and the other one in patients with brain metastases or primary central nervous system tumors / First detailed presentation of quality of life data from the Phase III ARAMIS trial of the investigational androgen receptor antagonist darolutamide in patients with non-metast...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Data from Bayer’s growing oncology portfolio include new analyses on the company’s precision oncology treatment larotrectinib, with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion: one on expanded data in pediatric patients and the other one in patients with brain metastases or primary central nervous system tumors / First detailed presentation of quality of life data from the Phase III ARAMIS trial of the investigational androgen receptor antagonist darolutamide in patients with non-metastatic castration-resistant prostate cancer / Oral presentation on investigational ATR i...
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news
It has in recent years been reported that microemulsion (ME) delivery systems provide an opportunity to improve the efficacy of a therapeutic agent whilst minimising side effects and also offer the advantage of favourable treatment regimens. The prostate ‐specific membrane antigen (PSMA) targeting agents PSMA‐11 and PSMA‐617, which accumulate in prostate tumours, allows for [68Ga]Ga3+‐radiolabelling and PET imaging of PSMA‐expressionin vivo. We herein report the formulation of [68Ga]Ga ‐PSMA‐617 into a ME ≤40 nm including its evaluation for improved cellular toxicity andin vivo biodistribution.The [68Ga]Ga...
Source: Journal of Labelled Compounds and Radiopharmaceuticals - Category: Biochemistry Authors: Tags: RESEARCH ARTICLE Source Type: research
This study aimed to explore novel biomarkers for GBM prognosis prediction. The gene expression profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets of GBM were downloaded. A total of 2241 overlapping differentially expressed genes (DEGs) were identified from TCGA and GSE7696 datasets. By univariate COX regression survival analysis, 292 survival-related genes were found among these DEGs (p
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
In this study, we reviewed major human studies on the health risks of radiation exposure and showed that sex-related factors may potentially influence the long-term response to radiation exposure. Available data suggest that long-term radiosensitivity in women is higher than that in men who receive a comparable dose of radiation. The report on the biological effects of ionizing radiation (BEIR VII) published in 2006 by the National Academy of Sciences, United States emphasized that women may be at significantly greater risk of suffering and dying from radiation-induced cancer than men exposed to the same dose of radiation....
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Abstract Evidence has been accumulating that, in men, some of the biological actions traditionally attributed to testosterone acting via the androgen receptor may in fact be dependent on its aromatisation to estradiol (E2). In men, E2 circulates at concentrations exceeding those of postmenopausal women, and estrogen receptors are expressed in many male reproductive and somatic tissues. Human studies contributing evidence for the role of E2 in men comprise rare case reports of men lacking aromatase or a functional estrogen receptor alpha, short term experiments manipulating sex steroid milieu in healthy men, men wi...
Source: European Journal of Endocrinology - Category: Endocrinology Authors: Tags: Eur J Endocrinol Source Type: research
Conclusions The recent, first randomized clinical trial demonstrated overall and progression free survival benefits after SBRT to oligometastatic disease which supports prior retrospective case series (6). The spine is a common site of metastatic bone disease, and as high quality data continue to mature, along with completion of additional randomized clinical trials, it is expected that utility of SBRT to the spine will increase in the future. Spine SBRT is unique due to the requirement of sharp dose falloff to prevent serious neurologic morbidity. With recent advances in radiotherapy planning, robotic patient positionin...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion and Future Perspectives This review illustrates our current knowledge of USP7, including its source and characterization, structure, binding partners and substrates in various biological processes. Besides, how USP7 regulates various aspects of a cell under both normal and pathological states are elaborated in detail. As the processes of ubiquitination and deubiquitination are extremely dynamic and context-specific, a series of studies have linked USP7 to different cancers. The biology, particularly the immune oncology mechanisms, reveal that USP7 inhibitors would be useful drugs, thus it is vital to develop hi...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Hormonal Therapy | Hormones | Neurology | Prostate Cancer | Radiation Therapy | Science